JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
US$ 218,42
arrow_downward
-1,81%(-4,03) 1D
US$ 218,42
0,00% (0,00)
bedtimeAfter-market
Fechado: 9 de out., 16:00:01 GMT-4 · USD
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para JAZZ…
Abrir
US$ 221,79
Alta
US$ 227,00
Baixa
US$ 213,20
Valor de mercado
14,18 bi
Volume médio
935,53 mil
Volume
1,29 mi
Índice P/L
14,93
Alto — 52 sem
US$ 266,38
Baixo — 52 sem
US$ 128,80
LPA
US$ 14,63
Beta
0,37
Ações em circulação
64,92 mi
Nº de funcionários
3 mil
Abrir
US$ 221,79
Alta
US$ 227,00
Baixa
US$ 213,20
Valor de mercado
14,18 bi
Volume médio
935,53 mil
Volume
1,29 mi
Índice P/L
14,93
Alto — 52 sem
US$ 266,38
Baixo — 52 sem
US$ 128,80
LPA
US$ 14,63
Beta
0,37
Ações em circulação
64,92 mi
Nº de funcionários
3 mil
Notícias
De fontes da web e parceiros de notícias
Investing.com Nigeria
·
há 5 horas
Form 144 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY For: 10 October
Traders Union
·
há 22 horas
Jazz Pharmaceuticals gets Cramer backing in CNBC stock call segment
TipRanks
·
há 1 dia
Jazz Pharmaceuticals Plans Commercial Leadership Transition Ahead
ChartMill
·
há 1 dia
Jazz Pharmaceuticals (NASDAQ:JAZZ): An Undervalued Biopharma Value Stock
Perfil
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Sobre Jazz Pharmaceuticals PLC